The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1468
ISSUE1468
May 11, 2015
Testosterone Nasal Gel (Natesto) for Hypogonadism
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Testosterone Nasal Gel (Natesto) for Hypogonadism
May 11, 2015 (Issue: 1468)
The FDA has approved an intranasal gel formulation of
testosterone (Natesto – Trimel/Endo) for replacement
therapy in men with hypogonadism. Packaged in a
metered-dose pump, Natesto is the first intranasal
testosterone to become available in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.